Global analysis of genetic variation in SLCO1B1

Pharmacogenomics

Volumn 9, Issue 1, 2008, Pages 19-33

  Pasanen, Marja K ^a   Neuvonen, Pertti J ^a   Niemi, Mikko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Genetic variation; OATP1B1; Organic anion transporting polypeptide; Pharmacogenetics; Polymorphism; SLCO1B1

Indexed keywords

ORGANIC ANION TRANSPORTER 2; DNA; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; AFRICA; ARTICLE; ASIA; ETHNIC DIFFERENCE; EUROPE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HUMAN; MIDDLE EAST; PACIFIC ISLANDS; POPULATION MIGRATION; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN HEMISPHERE; ALLELE; ETHNIC GROUP; GENE LINKAGE DISEQUILIBRIUM; GENETICS;

ALLELES; DNA; ETHNIC GROUPS; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; VARIATION (GENETICS);

EID: 40949126593     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.1.19     Document Type: Article

References (45)

1. Cui Y, König J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276(13), 9626-9630 (2001).
2. Ho RH, Kim RB: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78(3), 260-277 (2005).
3. Hsiang B, Zhu Y, Wang Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274(52), 37161-37168 (1999).
4. Abe T, Kakyo M, Tokui T et al.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274(24), 17159-17163 (1999).
5. Tirona RG, Leake BF, Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276(38), 35669-35675 (2001).
6. Tamai I, Nezu J, Uchino H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273(1), 251-260 (2000).
7. Liu L, Cui Y, Chung AY et al.: Vectorial transport of enalapril by OATP1A1/MRP2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J. Pharmacol. Exp. Ther. 318(1), 395-402 (2006).
8. Maeda K, Ieiri I, Yasuda K et al.: Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79(5), 427-439 (2006).
9. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10 -hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33(3), 434-439 (2005).
10. Nakagomi-Hagihara R, Nakai D, Kawai K et al.: OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab. Dispos. 34(5), 862-869 (2006).
11. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y: Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos. 34(7), 1247-1254 (2006).
12. Niemi M, Schaeffeler E, Lang T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14(7), 429-440 (2004).
13. Niemi M: Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8(7), 787-802 (2007).
14. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15(7), 513-522 (2005).
15. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304(1), 223-228 (2003).
16. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y: Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14(11), 749-757 (2004).
17. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16(12), 873-879 (2006).
18. Niemi M, Pasanen MK, Neuvonen PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80(4), 356-366 (2006).
19. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82(6), 726-733 (2007).
20. Niemi M, Kivistö KT, Hofmann U, Schwab M. Eichelbaum M, Fromm MF: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J. Clin. Pharmacol. 59(5). 602-604 (2005).
21. Niemi M, Backman JT, Kajosaari LI et al.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77(6), 468-478 (2005).
22. Nozawa T, Nakajima M, Tamai I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B ( SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302 (2), 804-813 (2002).
23. Pasanen MK, Backman JT, Neuvonen PJ, Niemi M: Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62 (6), 409-415 (2006).
24. Lee E, Ryan S, Birmingham B et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78(4), 330-341 (2005).
25. Jada SR, Xiaochen S, Yan LY et al.: Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur J. Clin. Pharmacol. 63(6), 555-563 (2007).
26. Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C ( SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol, Ther. 73(6), 554-565 (2003).
27. Mwinyi J, Johne A. Bauer S, Roots I, Gerloff T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75(5), 415-421 (2004).
28. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K: Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. (2007).
29. Tirona RG: Ethnic differences in statin disposition. Clin. Pharmacol. Ther. 78(4), 311-316 (2005).
30. Ho RH, Choi L, Lee W et al.: Effect of drug transporter genotypes on pravastatin disposition in European- and African - American participants. Pharmacogenet. Genomics 17(8), 647-656 (2007).
31. Cann HM, de Toma C, Cazes L et al.: A human genome diversity cell line panel. Science 296(5566), 261-262 (2002).
32. Ramachandran S, Deshpande O, Roseman CC et al.: Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa. Proc. Natl Acad. Sci. USA 102(44), 15942-15947 (2005).
33. Rósenberg NA, Pritchard JK, Weber JL et al.: Genetic structure of human populations. Science 298(5602), 2381-2385 (2002).
34. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68(4), 978-989 (2001).
35. Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003).
36. Excoffier L, Smouse PE, Quattro JM: Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. Genetics 131(2), 479-491 (1992).
37. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17(2), 93-101 (2007).
38. Romualdi C, Balding D, Nasidze IS et al.: Patterns of human diversity, within and among continents, inferred from biallelic DNA polymorphisms. Genome Res. 12 (4), 602-612 (2002).
39. Barbujani G, Magagni A, Minch E, Cavalli-Sforza LL: An apportionment of human DNA diversity. Proc. Natl Acad. Sci. USA 94(9), 4516-4519 (1997).
40. Jorde LB, Watkins WS, Barnshad MJ et al.: The distribution of human genetic diversity: a comparison of mitochondrial, autosomal. and Y-chromosome data. Am. J. Hum. Genet. 66(3), 979-988 (2000).
41. Chung JY, Cho JY, Yu KS et al.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78(4), 342-350 (2005).
42. Gerloff T, Schaefer M, Mwinyi J et al.: Influence of the SLCO1B1 *1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch. Pharmacol. 373(1), 45-50 (2006).
43. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565-581 (2006).
44. Niemi M, Neuvonen PJ, Hofmann U et al.: Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics 15(5), 303-309 (2005).
45. Morimoto K, Ueda S, Seki N et al.: OATP-C(OATP1B1)*15 is associated with statin induced myopathy in hypercholesterolemic patients. Clin. Pharmacol. Ther. 77 (2), P21 (2005).